Head-to-head evidence
Canagliflozin vs janagliflozin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: SGLT2 · full Type 2 Diabetes pipeline
Canagliflozin · Invokana
Marketed by Johnson & Johnson
NCT01032629 · Phase 3 · completed
The trial randomized 4,330 participants to canagliflozin or placebo with quadruple masking and used a hard clinical primary endpoint of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. Results were discordant across the prespecified comparisons: the 300-mg dose met the endpoint comparison, while the 100-mg dose and combined canagliflozin analysis did not.
Next expected readout: October 2026 · NCT07711171 (registry estimate)
janagliflozin
Developed by Sihuan Pharmaceutical Holdings
NCT03811548 · Phase 3 · status unknown
This randomized, double-blind, placebo-controlled trial enrolled 442 patients and measured change in HbA1c, a standard diabetes efficacy measure, at 24 weeks. Both the 25 mg and 50 mg doses of janagliflozin significantly outperformed placebo (p<0.001 for both), exceeding the trial's pre-specified superiority margin.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Canagliflozin's landscape · janagliflozin's landscape